;PMID: 9020195
;source_file_1730.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..37] = [t:0..37]
;1)sentence:[e:43..121] = [t:43..121]
;2)section:[e:125..178] = [t:125..178]
;3)section:[e:182..280] = [t:182..280]
;4)sentence:[e:284..383] = [t:284..383]
;5)sentence:[e:384..496] = [t:384..496]
;6)sentence:[e:497..650] = [t:497..650]
;7)sentence:[e:651..757] = [t:651..757]
;8)sentence:[e:758..924] = [t:758..924]
;9)sentence:[e:925..1058] = [t:925..1058]
;10)sentence:[e:1060..1174] = [t:1060..1174]
;11)sentence:[e:1175..1388] = [t:1175..1388]
;12)section:[e:1392..1436] = [t:1392..1436]

;section 0 Span:0..37
;Toxicology. 1997 Feb 14;117(1):13-23.
(SEC
  (FRAG (NNP:[0..10] Toxicology) (,:[10..11] .) (CD:[12..16] 1997)
        (NNP:[17..20] Feb) (CC:[21..28] 14;117-LRB-) (CD:[28..29] 1)
        (-RRB-:[29..30] -RRB-) (::[30..31] :) (CD:[31..36] 13-23) (.:[36..37] .)))

;sentence 1 Span:43..121
;Interaction of methadone with substrates of human hepatic cytochrome P450
;3A4.
;[58..67]:substance:"methadone"
;[73..83]:substance:"substrates"
;[101..120]:cyp450:"cytochrome P450 3A4"
(SENT
  (NP-SBJ
    (NP (NN:[43..54] Interaction))
    (PP (IN:[55..57] of)
      (NP (NN:[58..67] methadone)))
    (PP (IN:[68..72] with)
      (NP
        (NP (NNS:[73..83] substrates))
        (PP (IN:[84..86] of)
          (NP (JJ:[87..92] human) (JJ:[93..100] hepatic)
            
            (NML (NN:[101..111] cytochrome) (NN:[112..116] P450))
            (NN:[117..120] 3A4)))))
    (.:[120..121] .)))

;section 2 Span:125..178
;Iribarne C, Dreano Y, Bardou LG, Menez JF, Berthou F.
(SEC
  (FRAG (NNP:[125..133] Iribarne) (NNP:[134..135] C) (,:[135..136] ,)
        (NNP:[137..143] Dreano) (NNP:[144..145] Y) (,:[145..146] ,)
        (NNP:[147..153] Bardou) (NNP:[154..156] LG) (,:[156..157] ,)
        (NNP:[158..163] Menez) (NNP:[164..166] JF) (,:[166..167] ,)
        (NNP:[168..175] Berthou) (NNP:[176..178] F.)))

;section 3 Span:182..280
;Equipe d'Accueil EA 948, Laboratoires de Biochimie-Nutrition, Faculte de 
;medecine, Brest, France.
(SEC
  (FRAG (NN:[182..188] Equipe) (NN:[189..198] d'Accueil) (NNS:[199..201] EA)
        (CD:[202..205] 948) (,:[205..206] ,) (NNP:[207..219] Laboratoires)
        (IN:[220..222] de) (NNP:[223..233] Biochimie-)
        (NNP:[233..242] Nutrition) (,:[242..243] ,) (NNP:[244..251] Faculte)
        (IN:[252..254] de) (NN:[256..264] medecine) (,:[264..265] ,)
        (NNP:[266..271] Brest) (,:[271..272] ,) (NNP:[273..279] France)
        (.:[279..280] .)))

;sentence 4 Span:284..383
;Methadone, a synthetic drug, is one of the most widely used drugs for opiate 
;dependency treatment.
;[284..293]:substance:"Methadone"
;[307..311]:substance:"drug"
;[344..349]:substance:"drugs"
;[354..360]:substance:"opiate"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[284..293] Methadone))
      (,:[293..294] ,)
      (NP (DT:[295..296] a) (JJ:[297..306] synthetic) (NN:[307..311] drug)))
    (,:[311..312] ,)
    (VP (VBZ:[313..315] is)
      (NP-PRD
        (NP (CD:[316..319] one))
        (PP (IN:[320..322] of)
          (NP
            (NP (DT:[323..326] the)
              (ADJP
                (ADVP (RBS:[327..331] most) (RB:[332..338] widely))
                (VBN:[339..343] used))
              (NNS:[344..349] drugs))
            (PP (IN:[350..353] for)
              (NP
                (NML (NN:[354..360] opiate) (NN:[362..372] dependency))
                (NN:[373..382] treatment)))))))
    (.:[382..383] .)))

;sentence 5 Span:384..496
;This drug has been demonstrated to be extensively  metabolized by cytochrome
;P450 3A4 in human liver microsomes.
;[389..393]:substance:"drug"
;[450..469]:cyp450:"cytochrome P450 3A4"
(SENT
  (S
    (NP-SBJ-1 (DT:[384..388] This) (NN:[389..393] drug))
    (VP (VBZ:[394..397] has)
      (VP (VBN:[398..402] been)
        (VP (VBN:[403..415] demonstrated)
          (S
            (NP-SBJ-1 (-NONE-:[415..415] *))
            (VP (TO:[416..418] to)
              (VP (VB:[419..421] be)
                (ADVP (RB:[422..433] extensively))
                (VP (VBN:[435..446] metabolized)
                  (NP-1 (-NONE-:[446..446] *))
                  (PP (IN:[447..449] by)
                    (NP-LGS (NN:[450..460] cytochrome) (NN:[461..465] P450)
                            (NN:[466..469] 3A4)))
                  (PP-LOC (IN:[470..472] in)
                    (NP (JJ:[473..478] human) (NN:[479..484] liver)
                        (NNS:[485..495] microsomes))))))))))
    (.:[495..496] .)))

;sentence 6 Span:497..650
;Thus, the aim of  this in vitro study was to determine if methadone is an
;inhibitor of other P450s  characterized by their specific catalytic
;activities.
;[555..564]:substance:"methadone"
;[571..580]:substance:"inhibitor"
;[590..595]:cyp450:"P450s"
(SENT
  (S
    (ADVP (RB:[497..501] Thus))
    (,:[501..502] ,)
    (NP-SBJ-1
      (NP (DT:[503..506] the) (NN:[507..510] aim))
      (PP (IN:[511..513] of)
        (NP (DT:[515..519] this)
          (ADJP (FW:[520..522] in) (FW:[523..528] vitro))
          (NN:[529..534] study))))
    (VP (VBD:[535..538] was)
      (S-PRP-PRD
        (NP-SBJ-1 (-NONE-:[538..538] *))
        (VP (TO:[539..541] to)
          (VP (VB:[542..551] determine)
            (SBAR (IN:[552..554] if)
              (S
                (NP-SBJ (NN:[555..564] methadone))
                (VP (VBZ:[565..567] is)
                  (NP-PRD
                    (NP (DT:[568..570] an) (NN:[571..580] inhibitor))
                    (PP (IN:[581..583] of)
                      (NP
                        (NP (JJ:[584..589] other) (NNS:[590..595] P450s))
                        (VP (VBN:[597..610] characterized)
                          (NP (-NONE-:[610..610] *))
                          (PP (IN:[611..613] by)
                            (NP-LGS (PRP$:[614..619] their)
                                    (JJ:[620..628] specific)
                                    (JJ:[629..638] catalytic)
                                    (NNS:[639..649] activities))))))))))))))
    (.:[649..650] .)))

;sentence 7 Span:651..757
;Enzymatic activities  specific to P450 2E1, P450 1A, P450 2B and P450 2C were
;not inhibited by  methadone.
;[685..693]:cyp450:"P450 2E1"
;[695..702]:cyp450:"P450 1A"
;[704..711]:cyp450:"P450 2B"
;[716..723]:cyp450:"P450 2C"
;[747..756]:substance:"methadone"
(SENT
  (S
    (NP-SBJ-1
      (NP (JJ:[651..660] Enzymatic) (NNS:[661..671] activities))
      (ADJP (JJ:[673..681] specific)
        (PP (TO:[682..684] to)
          (NP
            (NP (NN:[685..689] P450) (NN:[690..693] 2E1))
            (,:[693..694] ,)
            (NP (NN:[695..699] P450) (NN:[700..702] 1A))
            (,:[702..703] ,)
            (NP (NN:[704..708] P450) (NN:[709..711] 2B))
            (CC:[712..715] and)
            (NP (NN:[716..720] P450) (NN:[721..723] 2C))))))
    (VP (VBD:[724..728] were) (RB:[729..732] not)
      (VP (VBN:[733..742] inhibited)
        (NP-1 (-NONE-:[742..742] *))
        (PP (IN:[743..745] by)
          (NP-LGS (NN:[747..756] methadone)))))
    (.:[756..757] .)))

;sentence 8 Span:758..924
;Conversely, nifedipine oxidation, mediated by cytochrome P450 3A4,  was
;potently inhibited by methadone by a mixed-type inhibition mechanism with a 
;Ki of 100 microM.
;[770..780]:substance:"nifedipine"
;[804..823]:cyp450:"cytochrome P450 3A4"
;[852..861]:substance:"methadone"
;[907..909]:quantitative-name:"Ki"
;[913..916]:quantitative-value:"100"
;[917..923]:quantitative-units:"microM"
(SENT
  (S
    (ADVP (RB:[758..768] Conversely))
    (,:[768..769] ,)
    (NP-SBJ-1
      (NP (NN:[770..780] nifedipine) (NN:[781..790] oxidation))
      (,:[790..791] ,)
      (VP (VBN:[792..800] mediated)
        (NP (-NONE-:[800..800] *))
        (PP (IN:[801..803] by)
          (NP-LGS (NN:[804..814] cytochrome) (NN:[815..819] P450)
                  (NN:[820..823] 3A4)))))
    (,:[823..824] ,)
    (VP (VBD:[826..829] was)
      (ADVP (RB:[830..838] potently))
      (VP (VBN:[839..848] inhibited)
        (NP-1 (-NONE-:[848..848] *))
        (PP (IN:[849..851] by)
          (NP-LGS (NN:[852..861] methadone)))
        (PP-MNR (IN:[862..864] by)
          (NP (DT:[865..866] a)
            (NML (VBN:[867..872] mixed) (HYPH:[872..873] -) (NN:[873..877] type))
            (NN:[878..888] inhibition) (NN:[889..898] mechanism)))
        (PP (IN:[899..903] with)
          (NP
            (NP (DT:[904..905] a) (NN:[907..909] Ki))
            (PP (IN:[910..912] of)
              (NP (CD:[913..916] 100) (NN:[917..923] microM)))))))
    (.:[923..924] .)))

;sentence 9 Span:925..1058
;Fluvoxamine, a new antidepressant, was shown to be a potent  mixed-type
;inhibitor of methadone N-demethylation with a Ki of 7 microM.
;[925..936]:substance:"Fluvoxamine"
;[944..958]:substance:"antidepressant"
;[997..1006]:substance:"inhibitor"
;[1010..1019]:substance:"methadone"
;[1043..1045]:quantitative-name:"Ki"
;[1049..1050]:quantitative-value:"7"
;[1051..1057]:quantitative-units:"microM"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[925..936] Fluvoxamine))
      (,:[936..937] ,)
      (NP (DT:[938..939] a) (JJ:[940..943] new) (NN:[944..958] antidepressant)))
    (,:[958..959] ,)
    (VP (VBD:[960..963] was)
      (VP (VBN:[964..969] shown)
        (S
          (NP-SBJ-1 (-NONE-:[969..969] *))
          (VP (TO:[970..972] to)
            (VP (VB:[973..975] be)
              (NP-PRD
                (NP (DT:[976..977] a) (JJ:[978..984] potent)
                  (NML (VBN:[986..991] mixed) (HYPH:[991..992] -)
                       (NN:[992..996] type))
                  (NN:[997..1006] inhibitor))
                (PP (IN:[1007..1009] of)
                  (NP (NN:[1010..1019] methadone)
                      (NN:[1020..1035] N-demethylation)))
                (PP (IN:[1036..1040] with)
                  (NP
                    (NP (DT:[1041..1042] a) (NN:[1043..1045] Ki))
                    (PP (IN:[1046..1048] of)
                      (NP (CD:[1049..1050] 7) (NN:[1051..1057] microM)))))))))))
    (.:[1057..1058] .)))

;sentence 10 Span:1060..1174
;Finally, methadone appears to be a mixed-type inhibitor and not a suicide 
;inhibitor of cytochrome P450 3A family.
;[1069..1078]:substance:"methadone"
;[1106..1115]:substance:"inhibitor"
;[1135..1144]:substance:"inhibitor"
;[1148..1166]:cyp450:"cytochrome P450 3A"
(SENT
  (S
    (ADVP (RB:[1060..1067] Finally))
    (,:[1067..1068] ,)
    (NP-SBJ (NN:[1069..1078] methadone))
    (VP (VBZ:[1079..1086] appears)
      (S
        (NP-SBJ (-NONE-:[1086..1086] *))
        (VP (TO:[1087..1089] to)
          (VP
            (VP (VB:[1090..1092] be)
              (NP-PRD (DT:[1093..1094] a)
                (NML (VBN:[1095..1100] mixed) (HYPH:[1100..1101] -)
                     (NN:[1101..1105] type))
                (NN:[1106..1115] inhibitor)))
            (CC:[1116..1119] and)
            (VP (RB:[1120..1123] not)
              (NP-PRD
                (NP (DT:[1124..1125] a) (NN:[1126..1133] suicide)
                    (NN:[1135..1144] inhibitor))
                (PP (IN:[1145..1147] of)
                  (NP
                    (NML
                      (NML (NN:[1148..1158] cytochrome) (NN:[1159..1163] P450))
                      (NN:[1164..1166] 3A))
                    (NN:[1167..1173] family)))))))))
    (.:[1173..1174] .)))

;sentence 11 Span:1175..1388
;Accordingly, caution should be advised  in the clinical use of methadone when
;other drugs are administered that are able  to induce or inhibit P450 3A4,
;such as rifampicin or nifedipine, diazepam and  fluvoxamine.
;[1238..1247]:substance:"methadone"
;[1259..1264]:substance:"drugs"
;[1318..1326]:cyp450:"P450 3A4"
;[1336..1346]:substance:"rifampicin"
;[1350..1360]:substance:"nifedipine"
;[1362..1370]:substance:"diazepam"
;[1376..1387]:substance:"fluvoxamine"
(SENT
  (S
    (ADVP (RB:[1175..1186] Accordingly))
    (,:[1186..1187] ,)
    (NP-SBJ-4 (NN:[1188..1195] caution))
    (VP (MD:[1196..1202] should)
      (VP (VB:[1203..1205] be)
        (VP (VBN:[1206..1213] advised)
          (NP-4 (-NONE-:[1213..1213] *))
          (PP (IN:[1215..1217] in)
            (NP
              (NP (DT:[1218..1221] the) (JJ:[1222..1230] clinical)
                  (NN:[1231..1234] use))
              (PP (IN:[1235..1237] of)
                (NP (NN:[1238..1247] methadone)))))
          (SBAR-TMP
            (WHADVP-3 (WRB:[1248..1252] when))
            (S
              (NP-SBJ-5
                (NP
                  (NP (JJ:[1253..1258] other) (NNS:[1259..1264] drugs))
                  (SBAR-6 (-NONE-:[1264..1264] *ICH*)))
                (PP-1 (-NONE-:[1264..1264] *ICH*)))
              (VP (VBP:[1265..1268] are)
                (VP (VBN:[1269..1281] administered)
                  (NP-5 (-NONE-:[1281..1281] *))
                  (SBAR-6
                    (WHNP-2 (WDT:[1282..1286] that))
                    (S
                      (NP-SBJ-2 (-NONE-:[1286..1286] *T*))
                      (VP (VBP:[1287..1290] are)
                        (ADJP-PRD (JJ:[1291..1295] able)
                          (S
                            (NP-SBJ (-NONE-:[1295..1295] *))
                            (VP (TO:[1297..1299] to)
                              (VP (VB:[1300..1306] induce) (CC:[1307..1309] or)
                                  (VB:[1310..1317] inhibit)
                                (NP (NN:[1318..1322] P450) (NN:[1323..1326] 3A4)))))))))
                  (,:[1326..1327] ,)
                  (PP-1 (JJ:[1328..1332] such) (IN:[1333..1335] as)
                    (NP
                      (NP (NN:[1336..1346] rifampicin))
                      (CC:[1347..1349] or)
                      (NP (NN:[1350..1360] nifedipine) (,:[1360..1361] ,)
                          (NN:[1362..1370] diazepam) (CC:[1371..1374] and)
                          (NN:[1376..1387] fluvoxamine))))
                  (ADVP-TMP-3 (-NONE-:[1387..1387] *T*)))))))))
    (.:[1387..1388] .)))

;section 12 Span:1392..1436
;PMID: 9020195 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1392..1396] PMID) (::[1396..1397] :) (CD:[1398..1405] 9020195)
        (NN:[1406..1407] -LSB-) (NNP:[1407..1413] PubMed) (::[1414..1415] -)
        (NN:[1416..1423] indexed) (IN:[1424..1427] for)
        (NNP:[1428..1436] MEDLINE-RSB-)))
